American Journal of Clinical Dermatology

, Volume 15, Issue 2, pp 77–86 | Cite as

Treatment of Acne in Children

Therapy in Practice

Abstract

Acne is a common skin condition in adolescents. It is not uncommon in childhood and it persists into adulthood. A broad range of acne treatments are available and have been shown to be safe and effective in adolescents and adults. However, there is limited literature regarding acne treatment in childhood and its available therapeutic options. It seems reasonable to extrapolate findings of the various studies reported on treatment of acne in the adolescent and adult age group, with the exclusion of the use of tetracycline derivatives. As clinicians, we must be more familiar with the clinical presentation of acne and available treatment options in our younger patients. Early recognition of acne with prompt and appropriate initiation of therapy in childhood will help prevent severe scarring in children.

References

  1. 1.
    Mancini AJ, Balwin HE, Eichenfield LF, et al. Acne life cycle: the spectrum of pediatric disease. Semin Cutan Surg. 2011;30:S2–5.CrossRefGoogle Scholar
  2. 2.
    Antoniou C, Dessinioti C, Stratigos AJ, Katsambas AD. Clinical and therapeutic approach to childhood acne: an update. Pediatr Dermatol. 2009;26(4):373–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Katsambas AD, Katoulis AC. Stavropoulos. Acne neonatorum: a study of 22 cases. Int J Dermatol. 1999;38:128–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology. 2003;206(1):24–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Lucky AW. A review of infantile and pediatric acne. Dermatology. 1998;196:95–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Rapelanoro R, Mortureux P, Couprie B, et al. Neonatal Malassezia furfur pustulosis. Arch Dermatol. 1996;132(2):190–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Ayhan M, Sancak B, Karaduman A, et al. Colonization of neonate skin by Malassezia species: relationship with neonatal cephalic pustulosis. J Am Acad Dermatol. 2007;57:1012–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Hello M, Prey S, Léauté-Labrèze C, Khammari A, et al. Infantile acne: a retrospective study of 16 cases. Pediatr Dermatol. 2008;25(4):434–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29 patients with infantile acne. Br J Dermatol. 2001;145:463–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Chew EW, Bingham A, Burrows D. Incidence of acne vulgaris in patients with infantile acne. Clin Exp Dermatol. 1990;15(5):376–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Tasli L, Turgut S, Kacar N, et al. Insulin-like growth factor-1 gene polymorphism in acne vulgaris. J Eur Acad Dermatol Venereol. 2013 Feb;27(2):254–7.Google Scholar
  12. 12.
    Mann MW, Ellis SS, Mallory SB. Infantile acne as the initial sign of an adrenocortical tumor. J Am Acad Dermatol. 2007;56(2):S15–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Jansen T, Burgdorf WHC, Plewig G. Pathogenesis and treatment of acne in childhood. Pediatr Dermatol. 1997;14:17–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Mourelatos K, Eady EA, Cunliffe WJ, et al. Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne. Br J Dermatol. 2007;156(1):22–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee DJ, Van Dyke GS, Kim J. Update on pathogenesis and treatment of acne. Curr Opin Pediatr. 2003;15:405–10.PubMedCrossRefGoogle Scholar
  16. 16.
    Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of denydroepiandrosterone. Arch Dermatol. 1994;130(3):308–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Stewart ME, Downing DT, Cook JS, et al. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol. 1992;128(10):1345–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr. 1997;130(1):30–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Schroeder B. Early diagnosis, presenting complaints, and management of hyperandrogenism in adolescents. Curr Womens Health Rep. 2001;1:124–30.PubMedGoogle Scholar
  20. 20.
    Degitz K, Placzek M, Arnold B, Schmidt H, Plewig G. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol. 2003;148(6):1263–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Friedlander SF, Baldwin HE, Mancini AJ, et al. The acne continuum: an aged-based approach to therapy. Semin Cutan Med Surg. 2011;30(Suppl 3):S6–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10(16):2555–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Decker LC, Deuel DM, Sedlock DM. Role of lipids in augmenting the antibacterial activity of benzoyl peroxide against Propionibacterium acnes. Antimicrob Agents Chemother. 1989;33:26–30.Google Scholar
  24. 24.
    Plewig G, Jansen T. Acne and rosacea. Berlin: Springer; 2000.CrossRefGoogle Scholar
  25. 25.
    Cove JH, Holland KT. The effect of benzoyl peroxide on cutaneous micro-organisms in vitro. J Appl Bacteriol. 1983;54:379–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun. 1985;49:116–21.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Hegemann L, Toso SM, Kitay K, Webster GF. Anti-inflammatory actions of benzoyl peroxide effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and almodulin. Br J Dermatol. 1994;130:569–75.PubMedCrossRefGoogle Scholar
  28. 28.
    Merker PC. Benzoyl peroxide: a history of early research and researchers. Int J Dermatol. 2002;41:185–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad spectrum antimicrobial agent. Int J Dermatol. 1977;16(5):413–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Gupta AK, Lynde CW, Kunynetz RA, et al. A randomised, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3 % erythromycin/5 % benzoyl peroxide and 0.025 % tretinoin/erythromycin 4 % in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Cunliffe WJ, Stainton C, Forster RA. Topical benzoyl peroxide increases the sebum excretion rate in patients with acne. Br J Dermatol. 1983;109:577–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Pierard-Franchimont C, Melotte P, Pierard GE. Topical benzoyl peroxide increases the sebum excretion rate. Br J Dermatol. 1984;110:506.PubMedCrossRefGoogle Scholar
  33. 33.
    Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Langner A, Chu A, Goulden V, Ambroziak M. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol. 2008;158:122–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117–33.PubMedCrossRefGoogle Scholar
  36. 36.
    Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5(1):37–42.PubMedGoogle Scholar
  37. 37.
    Eichenfield LF, Draelos Z, Lucky AW, et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. J Drugs Dermatol. 2013;12(6):611–8.PubMedGoogle Scholar
  38. 38.
    Robison HM Jr. Role of antibiotics in therapy of acne. AMA Arch Derm Syphilol. 1954;69(4):414–7.CrossRefGoogle Scholar
  39. 39.
    Cantatore-Francis JL, Glick SA. Childhood acne: evaluation and management. Dermatol Ther. 2006;19(4):202–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Yan AC, Baldwin HE, Eichenfield LF, et al. Approach to pediatric acne treatment: an update. Semin Cutan Med Surg. 2011;30:S16–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol. 1984;120(10):1308–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010;9(6):655–64.PubMedGoogle Scholar
  43. 43.
    Tom WL, Friedlander SF. Acne through the ages: case-based observations through childhood and adolescence. Clin Pediatr (Phila). 2008;47(7):639–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Davis SA, Sandoval LF, Gustafson CJ, et al. Treatment of preadolescent acne in the United States: an analysis of nationally representative data. Pediatr Dermatol. 2013;30(6):689–94.Google Scholar
  45. 45.
    Witkop CJ Jr, Wolf RO. Hypoplasia and intrinsic staining of enamel following tetracycline therapy. JAMA. 1963;185:1008–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Simmons DJ, Chang SL, Russell JE, et al. The effect of protracted tetracycline treatment on bone growth and maturation. Clin Orthop Relat Red. 1983;180:253–9.Google Scholar
  47. 47.
    Dreno B, Bettoli V, Ochsendorf F, et al. European expert group on oral antibiotics in acne. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391–9.PubMedGoogle Scholar
  48. 48.
    Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol. 2011;4(2):40–7.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011;34(10):821–37.PubMedCrossRefGoogle Scholar
  50. 50.
    Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced pill esophagitis. Dis Esophagus. 2004;17(2):168–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Jarvinen A, Nykanen S, Paasiniemi L, et al. Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline. Clin Drug Investig. 1985;10(6):323–7.CrossRefGoogle Scholar
  52. 52.
    Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol. 2009;145(1):63–6.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Antonov D, Kazandjieoa J, Etugov D. Drug-induced lupus erythematosus. Clin Dermatol. 2004;22(2):157–66.PubMedCrossRefGoogle Scholar
  54. 54.
    Knowles S, Shapiro L, Shear NH. Serious dermatologic reactions in children. Curr Opin Pediatr. 1997;9(4):388–95.PubMedCrossRefGoogle Scholar
  55. 55.
    Gordon G, Sparano BM, Iatropoulos MJ. Hyperpigmentation of the skin associated with minocycline therapy. Arch Dermatol. 1985;121(5):618–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(6):718–25.PubMedCrossRefGoogle Scholar
  57. 57.
    Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005;6(1):29–37.PubMedCrossRefGoogle Scholar
  58. 58.
    Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using a objective method for recording erythema. Br J Dermatol. 1994;130:356–60.PubMedCrossRefGoogle Scholar
  59. 59.
    Poli F. Acne on pigmented skin. Int J Dermatol. 2007;46(1):39–41.PubMedCrossRefGoogle Scholar
  60. 60.
    Turowski CB, James WD. The efficacy and safety of amoxicillin, trimethoprim sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris. Adv Dermatol. 2007;23:155–63.PubMedCrossRefGoogle Scholar
  61. 61.
    Fenner JA, Wiss K, Levin NA. Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol. 2008;25(2):179–83.PubMedCrossRefGoogle Scholar
  62. 62.
    Gruber F, Grubisic-Greblo H, Kastelan M, et al. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-oustulosa. J Chemother. 1998;10:469–73.PubMedCrossRefGoogle Scholar
  63. 63.
    Babaeinejad S. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age? J Dermatol Treat. 2011;22(4):206–10.CrossRefGoogle Scholar
  64. 64.
    Maleszka R, Turek-Urasinska K, Oremus M, et al. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized double-blind, noninferiority study. Skinmed. 2011;9(2):86–94.PubMedGoogle Scholar
  65. 65.
    Singhi MK, Ghiya BC, Dhabhai RK. Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris. Indian J Derm Venereol Leprol. 2003;69(4):274–6.Google Scholar
  66. 66.
    Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30(3):215–20.PubMedCrossRefGoogle Scholar
  67. 67.
    Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol. 2001;28(1):1–4.PubMedGoogle Scholar
  68. 68.
    Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat. 2006;17(4):217–21.PubMedCrossRefGoogle Scholar
  69. 69.
    Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis. 2007;79(6):430–4.PubMedGoogle Scholar
  70. 70.
    Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother. 2005;6(3):409–18.PubMedCrossRefGoogle Scholar
  71. 71.
    Kligman AM, Fulton JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469–76.Google Scholar
  72. 72.
    Baldwin HE, Nighland M, Kendall C, Mays DA, et al. 40 years of topical tretinoin use in review. J Drugs Dermatol. 2013;12(6):638–42.PubMedGoogle Scholar
  73. 73.
    Bergfeld WF. The evolving role of retinoids in the management of cutaneous conditions. Clinician. 1998;16:1–32.Google Scholar
  74. 74.
    Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3 Suppl):S200–10.Google Scholar
  75. 75.
    Eichenfield LF, Matiz C, Funk A, Dill SW. Study of the efficacy and tolerability of 0.04 % tretinoin microsphere gel for preadolescent acne. Pediatrics. 2010;125:e1316–23.PubMedCrossRefGoogle Scholar
  76. 76.
    Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54(1):73–81.PubMedCrossRefGoogle Scholar
  77. 77.
    Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(suppl 52):8–11.PubMedCrossRefGoogle Scholar
  78. 78.
    Kose O, Koc E, Arca E. Adapalene gel 0.1 % in the treatment of infantile acne: an open clinical study. Pediatr Dermatol. 2008;25(3):383–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Cunliffe WJ, Poncet M, Loesche C, Vershoore M. A comparison of the efficacy and tolerability of adapalene 0.1 % gel versus tretinoin 0.025 % gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48–56.PubMedCrossRefGoogle Scholar
  80. 80.
    Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescent. J Am Acad Dermatol. 2003;49(2):171–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Strachan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol. 2009;145(7):797–9.Google Scholar
  82. 82.
    Torrelo A, Pastor MZ, Zambrano A. Severe acne infantum successfully treated with isotretinoin. Pediatr Dermatol. 2005;22(4):357–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Sarazin F, Dompmartin A, Nivot S, et al. Treatment of infantile acne with oral isotretinoin. Eur J Dermatol. 2004;14(1):71–2.PubMedGoogle Scholar
  84. 84.
    Léauté-Labrèze C, Gautier C, Labbé L, Taieb A. Infantile acne and isotretinoin. Ann Dermatol Venereol. 1998;125(2):132–4.PubMedGoogle Scholar
  85. 85.
    Arbegast KD, Braddock SW, Lamberty LF, Sawka AR. Treatment of infantile cystic acne with oral isotretinoin: a case report. Pediatr Dermatol. 1991;8(2):166–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Lewis-Jones MS. Results of a U.K. consultant dermatologist postal survey in infantile acne. Br J Dermatol. 2000;143(57):128.Google Scholar
  87. 87.
    Ward A, Brodgen RN, Heel RC, et al. Isotretinoin: a review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs. 1984;28(1):6–37.PubMedCrossRefGoogle Scholar
  88. 88.
    Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne. Br J Dermatol. 2005;153(6):1126–36.PubMedCrossRefGoogle Scholar
  89. 89.
    Digiovanna JJ, Mauro T, Milstone LM, et al. Systemic retinoids in the management of ichthyosis and related skin types. Dermatol Ther. 2013;26(1):26–38.PubMedCrossRefGoogle Scholar
  90. 90.
    Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1):15–20.PubMedGoogle Scholar
  91. 91.
    Yentzer BA, Fountain JM, Clark AR, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010;86(2):103–8.PubMedGoogle Scholar
  92. 92.
    Mengesha YM, Hansen RC. Toddler-age nodulocystic acne. J Peadiatr. 1999;134(5):644–8.CrossRefGoogle Scholar
  93. 93.
    Barnes CJ, Eichenfield LF, Lee J, Cunningham BB. A practical approach for the use of oral isotretinoin for infantile acne. Pediatr Dermatol. 2005;22(2):166–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Stainforth JM, Layton AM, Taylor JP, et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol. 1993;129:297–301.PubMedCrossRefGoogle Scholar
  95. 95.
    Goldsmith LA, Bolognia JL, Callen JP, et al. American academy of dermatology consensus conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004;50(6):900–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Dermatology (W406)Aberdeen Royal InfirmaryForesterhillUK
  2. 2.Division of Applied MedicineUniversity of AberdeenForesterhillUK

Personalised recommendations